...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Antimicrobial agents and chemotherapy. >In vitro activity of doripenem against Burkholderia cepacia complex isolates from non-cystic fibrosis patients.
【24h】

In vitro activity of doripenem against Burkholderia cepacia complex isolates from non-cystic fibrosis patients.

机译：多瑞培南对非囊性纤维化患者的伯克霍尔德菌洋葱复合体的体外活性。

获取原文
获取原文并翻译 | 示例
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Burkholderia cepacia complex (BCC), a group of nonfer-menting Gram-negative bacilli (NFGNB), is emerging as an important nosocomial pathogen. It causes a wide variety of infections, such as pneumonia (especially in patients with cystic fibrosis), meningitis, and septicemia. These infections are often difficult to treat due to high intrinsic antimicrobial resistance in BCC and the lack of effective antibiotics. BCC is resistant to aminoglycosides, antipseudomonal penicillins, and cephalosporins (4). Hence, the need for new agents active against this pathogen has become critical for patient care.In recent years, carbapenems have assumed a greater therapeutic role for multidrug-resistant (MDR) isolates. Dorip-enem is a new broad-spectrum intravenous 1-p-methyl carbap-enem. It has high activity against many Gram-positive and -negative organisms, including NFGNB. Against Pseudomonas aeruginosa, doripenem exhibits rapid bactericidal activity, with 2- to 4-fold-lower MICs than those of meropenem. However, the activity of doripenem against BCC has not been reported much, and present susceptibility reports are mainly from isolates of cystic fibrosis patients (6). Isolation of BCC from blood of non-CF septicemic patients is on the rise in our region (3), and the in vitro activity of doripenem against these isolates has been studied.
机译：伯克霍尔德菌洋葱复合体（BCC）是一组非发酵性革兰氏阴性杆菌（NFGNB），正在作为重要的医院病原体出现。它会引起多种感染，例如肺炎（尤其是囊性纤维化患者），脑膜炎和败血病。由于BCC固有的高抗药性和缺乏有效的抗生素，这些感染通常很难治疗。 BCC对氨基糖苷类，抗假性青霉素和头孢菌素具有抗性（4）。因此，对这种病原体具有活性的新药物的需求已成为患者护理的关键。近年来，碳青霉烯类药物已对多药耐药（MDR）分离株发挥了更大的治疗作用。 Dorip-enem是一种新型的广谱静脉内1-p-甲基carbap-enem。它对许多革兰氏阳性和阴性生物（包括NFGNB）具有高活性。对铜绿假单胞菌而言，多瑞培南具有快速的杀菌活性，其MIC比美罗培南的MIC低2-4倍。但是，多瑞培南抗BCC的活性报道很少，目前的敏感性报告主要来自囊性纤维化患者的分离株（6）。从非CF败血病患者的血液中分离出BCC在我们地区正在增加（3），并且已经研究了多瑞培南针对这些分离物的体外活性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号